Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, Forecast & News

$5.93
-0.05 (-0.84 %)
(As of 01/24/2020 02:33 AM ET)
Today's Range
$5.86
Now: $5.93
$6.05
50-Day Range
$5.83
MA: $6.11
$6.58
52-Week Range
$5.58
Now: $5.93
$9.20
Volume112,400 shs
Average Volume193,527 shs
Market Capitalization$130.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.36 million
Book Value$2.41 per share

Profitability

Net Income$-38,820,000.00
Net Margins-631.96%

Miscellaneous

Employees75
Market Cap$130.08 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) posted its quarterly earnings data on Tuesday, November, 19th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.09. The biotechnology company earned $1.40 million during the quarter, compared to analysts' expectations of $1.75 million. REDHILL BIOPHAR/S had a negative net margin of 631.96% and a negative return on equity of 103.63%. View REDHILL BIOPHAR/S's Earnings History.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for REDHILL BIOPHAR/S.

What price target have analysts set for RDHL?

3 brokers have issued 12-month price targets for REDHILL BIOPHAR/S's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate REDHILL BIOPHAR/S's stock price to reach $19.33 in the next year. This suggests a possible upside of 226.0% from the stock's current price. View Analyst Price Targets for REDHILL BIOPHAR/S.

What is the consensus analysts' recommendation for REDHILL BIOPHAR/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for REDHILL BIOPHAR/S.

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

Headlines about RDHL stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. REDHILL BIOPHAR/S earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for REDHILL BIOPHAR/S.

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the folowing people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.22%) and Ingalls & Snyder LLC (0.09%).

Which major investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC.

Which major investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was acquired by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $5.93.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $130.08 million and generates $8.36 million in revenue each year. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe.View Additional Information About REDHILL BIOPHAR/S.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is http://www.redhillbio.com/.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131.


MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  377 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel